Japanese 
English 
Our CEO, Takahara, recently appeared on IRTV, a video platform connecting investors and companies. YouTube: IRTV – “July 2, 2024 IPO! Discover the Secrets of PepMetics® Technology: A New Era in Drug Discovery” https://youtu.be/7_xlnd5ECQ4
アーカイブ: ニュース
「次世代創薬における要素技術の「ケミストリー」 ～AI、オートメーション、 分子変換の融合～」登壇のお知らせ
On Wednesday, November 13, 2024, our CTO, Toma, delivered a presentation at the symposium titled “Chemistry in Next-Generation Drug Discovery: Fusion of AI, Automation, and Molecular Conversion.” The event was co-hosted by LINK-J and Merck Ltd. Japan, and took place both at the Nihonbashi Life Science Hub and online. Read the full event report here:...
ラジオNIKKEI出演のお知らせ
We’re excited to share that our CEO, Takehara, was featured on Radio NIKKEI’s program, Leaders in Business: Ifu Dodo. Tune in to hear his insights on October 23rd, Wednesday, from 16:40 to 17:00 on Radio NIKKEI 1. You can listen to the October 23rd broadcast via the “Apple Podcasts” or “Spotify” links on the right...
CITELINE Japan Award 2024 Biotech company of the year ファイナリストに選出
We are honored to announce that we’ve been chosen as a finalist for the prestigious Biotech Company of the Year at the CITELINE Japan Award 2024, which celebrates exceptional achievements and groundbreaking innovation in the pharmaceutical and biotech industries. Read More
日本経済新聞掲載のお知らせ
日本経済新聞に当社の記事が掲載されました。「創薬のプリズムバイオラボに熱視線 メガファーマも評価」
当社とエーザイの共同創出品E7386についてESMO（欧州臨床腫瘍学会）年次総会においてエーザイが発表
TOKYO, Japan, 9 September 2024: — PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the interim analysis of a combination study of E7386, created through collaboration research with Eisai Co., Ltd., and Lenvatinib mesylate ( “lenvatinib”) will be presented...
東京オフィス開設のご案内
We are pleased to announce the establishment of PRISM BioLab Co., Ltd. Tokyo office. The office was officially opened on September 2, 2024 and will serve as a base for our business and administrative functions, for enhanced communications with our investors and partners, and to enable more effective business decisions. We sincerely appreciate the continued...
東京証券取引所グロース市場へ新規上場のお知らせ
PRISM BioLab Corporation is pleased to announce its initial listing on the Tokyo Stock Exchange Growth Market today. We would like to take this opportunity to express our sincere gratitude to all our stakeholders for their unwavering support and cooperation. For more details regarding our new listing, please visit the Tokyo Stock Exchange website. https://www.jpx.co.jp/listing/stocks/new/index.html...
東京証券取引所グロース市場への上場承認に関するお知らせ
PRISM BioLab is pleased to announce that the Tokyo Stock Exchange today approved the initial listing of our shares on the Growth Market of the Tokyo Stock Exchange. Read Full Press Release-Japanese Text Only
PRISM BioLab、小野薬品工業 とのライセンス契約締結のお知らせ
TOKYO, Japan, 25 Apr 2024: — PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and licensing agreement with ONO PHARMACEUTICAL CO., LTD. . Read Full Press Release